Anirudh Khanna
Interventional Cardiology · Hackettstown, NJNPI 1104909712
Payments from drug & device makers
Across 256 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$547
- Boehringer Ingelheim$461
- Pfizer$419
- Amgen$345
- Boston Scientific$322
- Merck$309
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,40699%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $547 |
| Boehringer Ingelheim | 18 | $461 |
| Pfizer | 28 | $419 |
| Amgen | 20 | $345 |
| Boston Scientific | 15 | $322 |
| Merck | 20 | $309 |
| Johnson & Johnson | 20 | $252 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $192 |
| E.r. Squibb & Sons, L.L.C. | 12 | $190 |
| Novo Nordisk | 8 | $162 |
| Sanofi-aventis U.S. LLC | 10 | $145 |
| Scpharmaceuticals Inc. | 7 | $128 |
| Alnylam Pharmaceuticals Inc. | 7 | $126 |
| AstraZeneca | 8 | $117 |
| Lexicon Pharmaceuticals, Inc. | 4 | $102 |
| Esperion Therapeutics, Inc. | 6 | $89 |
| Bayer | 4 | $73 |
| Regeneron Healthcare Solutions, Inc. | 4 | $55 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Abbott | 2 | $46 |
| Bardy Diagnostics, Inc. | 1 | $45 |
| Altathera Pharmaceuticals LLC | 2 | $39 |
| Atricure, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 2 | $24 |
| Medtronic | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $11 |
How this compares
$4,432 in reported general payments places this provider in the 25th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 632 | $723,663 |
| XareltoRivaroxaban | 243 | $272,623 |
| EntrestoSacubitril/Valsartan | 101 | $147,389 |
| FarxigaDapagliflozin Propanediol | 36 | $43,569 |
| MultaqDronedarone Hcl | 23 | $34,692 |
| Repatha SureclickEvolocumab | 23 | $32,610 |
| JardianceEmpagliflozin | 27 | $27,020 |
| Metoprolol Succinate | 1,058 | $19,339 |
| Repatha PushtronexEvolocumab | 14 | $15,517 |
| BrilintaTicagrelor | 16 | $14,224 |
| Rosuvastatin Calcium | 674 | $11,104 |
| Atorvastatin Calcium | 984 | $9,474 |
| Valsartan | 272 | $9,139 |
| Amlodipine Besylate | 938 | $6,476 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $5,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $419 | $723,663632 claims |
| Johnson & JohnsonXarelto | $252 | $272,623243 claims |
| NovartisEntresto | $547 | $147,389101 claims |
| AstraZenecaFarxiga, Brilinta | $117 | $57,79352 claims |
| Sanofi-aventis U.S. LLCMultaq | $145 | $34,69223 claims |
| Boehringer IngelheimJardiance | $461 | $27,02027 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $16 | $5,90212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Hackettstown
- Dinesh SingalSomerset$1.4M
- Ankitkumar PatelGlen Ridge$717K
- Matthew SayboltEatontown$671K
- Jaffar RazaSecaucus$537K
- Kintur SanghviBordentown$467K
- Ziad AbbudOcean$361K
- Ramin HastingsHasbrouck Heights$355K
- Ryan KapleHackensack$280K
- Haroon FarazTeaneck$269K
- Darshan GodkarCedar Knolls$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.